119 related articles for article (PubMed ID: 20461809)
1. Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients.
Pisani V; Moschella V; Bari M; Fezza F; Galati S; Bernardi G; Stanzione P; Pisani A; Maccarrone M
Mov Disord; 2010 May; 25(7):920-4. PubMed ID: 20461809
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy.
Romigi A; Bari M; Placidi F; Marciani MG; Malaponti M; Torelli F; Izzi F; Prosperetti C; Zannino S; Corte F; Chiaramonte C; Maccarrone M
Epilepsia; 2010 May; 51(5):768-72. PubMed ID: 19817812
[TBL] [Abstract][Full Text] [Related]
3. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients.
Pisani A; Fezza F; Galati S; Battista N; Napolitano S; Finazzi-Agrò A; Bernardi G; Brusa L; Pierantozzi M; Stanzione P; Maccarrone M
Ann Neurol; 2005 May; 57(5):777-9. PubMed ID: 15852389
[No Abstract] [Full Text] [Related]
4. Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms.
Morgan CJ; Page E; Schaefer C; Chatten K; Manocha A; Gulati S; Curran HV; Brandner B; Leweke FM
Br J Psychiatry; 2013 May; 202(5):381-2. PubMed ID: 23580381
[TBL] [Abstract][Full Text] [Related]
5. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis.
Koethe D; Giuffrida A; Schreiber D; Hellmich M; Schultze-Lutter F; Ruhrmann S; Klosterkötter J; Piomelli D; Leweke FM
Br J Psychiatry; 2009 Apr; 194(4):371-2. PubMed ID: 19336792
[TBL] [Abstract][Full Text] [Related]
6. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.
Leweke FM; Giuffrida A; Koethe D; Schreiber D; Nolden BM; Kranaster L; Neatby MA; Schneider M; Gerth CW; Hellmich M; Klosterkötter J; Piomelli D
Schizophr Res; 2007 Aug; 94(1-3):29-36. PubMed ID: 17566707
[TBL] [Abstract][Full Text] [Related]
7. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
van der Stelt M; Fox SH; Hill M; Crossman AR; Petrosino S; Di Marzo V; Brotchie JM
FASEB J; 2005 Jul; 19(9):1140-2. PubMed ID: 15894565
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms.
Giuffrida A; Leweke FM; Gerth CW; Schreiber D; Koethe D; Faulhaber J; Klosterkötter J; Piomelli D
Neuropsychopharmacology; 2004 Nov; 29(11):2108-14. PubMed ID: 15354183
[TBL] [Abstract][Full Text] [Related]
9. Normal cerebrospinal fluid levels of insulin in patients with Parkinson's disease.
Jiménez-Jiménez FJ; Molina JA; Vargas C; Gómez P; De Bustos F; Zurdo M; Gómez-Escalonilla C; Barcenilla B; Berbel A; Camacho A; Arenas J
J Neural Transm (Vienna); 2000; 107(4):445-9. PubMed ID: 11215755
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid cyclic guanosine 3'5' monophosphate levels in Parkinson's disease.
Navarro JA; Jiménez-Jiménez FJ; Molina JA; Benito-León J; Cisneros E; Gasalla T; Ortí-Pareja M; Tallón-Barranco A; de Bustos F; Arenas J
J Neurol Sci; 1998 Feb; 155(1):92-4. PubMed ID: 9562329
[TBL] [Abstract][Full Text] [Related]
11. Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity.
Patel S; Rademacher DJ; Hillard CJ
J Pharmacol Exp Ther; 2003 Sep; 306(3):880-8. PubMed ID: 12808005
[TBL] [Abstract][Full Text] [Related]
12. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
[TBL] [Abstract][Full Text] [Related]
13. Excessive daytime sleepiness in de novo and treated Parkinson's disease.
Fabbrini G; Barbanti P; Aurilia C; Vanacore N; Pauletti C; Meco G
Mov Disord; 2002 Sep; 17(5):1026-30. PubMed ID: 12360553
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of anandamide hydrolysis does not rescue respiratory abnormalities observed in an animal model of Parkinson's disease.
Batista LA; Cabral LM; Moreira TS; Takakura AC
Exp Physiol; 2022 Feb; 107(2):161-174. PubMed ID: 34907627
[TBL] [Abstract][Full Text] [Related]
15. Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease.
Storch A; Wolz M; Beuthien-Baumann B; Löhle M; Herting B; Schwanebeck U; Oehme L; van den Hoff J; Perick M; Grählert X; Kotzerke J; Reichmann H
Neurology; 2013 May; 80(19):1754-61. PubMed ID: 23576623
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease.
Jiménez-Jiménez FJ; Molina JA; Aguilar MV; Meseguer I; Mateos-Vega CJ; González-Muñoz MJ; de Bustos F; Martínez-Salio A; Ortí-Pareja M; Zurdo M; Martínez-Para MC
J Neural Transm (Vienna); 1998; 105(4-5):497-505. PubMed ID: 9720977
[TBL] [Abstract][Full Text] [Related]
17. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease.
Olanow CW; Gauger LL; Cedarbaum JM
Ann Neurol; 1991 May; 29(5):556-9. PubMed ID: 1859185
[TBL] [Abstract][Full Text] [Related]
18. The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease.
Mokhles MM; Trifirò G; Dieleman JP; Haag MD; van Soest EM; Verhamme KM; Mazzaglia G; Herings R; Luise Cd; Ross D; Brusselle G; Colao A; Haverkamp W; Schade R; Camp Gv; Zanettini R; Sturkenboom MC
Pharmacol Res; 2012 Mar; 65(3):358-64. PubMed ID: 22123498
[TBL] [Abstract][Full Text] [Related]
19. Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson's disease: effects of dopaminergic treatment.
Brunner H; Wetter TC; Hogl B; Yassouridis A; Trenkwalder C; Friess E
Mov Disord; 2002 Sep; 17(5):928-33. PubMed ID: 12360541
[TBL] [Abstract][Full Text] [Related]
20. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
